NCT05995769 (PAP-AUD) is a Phase 2 clinical trial of Psilocybin in Alcohol Use Disorder, sponsored by University of Calgary.

Who is sponsoring NCT05995769?

NCT05995769 is sponsored by University of Calgary.

What drugs are being tested in NCT05995769?

Interventions in NCT05995769: Psilocybin.

What condition does NCT05995769 study?

NCT05995769 studies Alcohol Use Disorder, Alcoholism.

Is NCT05995769 still recruiting?

NCT05995769 is currently recruiting now. Last updated 7 May 2024.

Last reviewed 2024-05-07 · How we verify

NCT05995769: PAP-AUD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder

Recruiting now Phase 2 Last updated 7 May 2024

What this trial tests

Phase 2 trial testing Psilocybin in Alcohol Use Disorder in 128 participants. Currently enrolling.

Timeline

20 March 2024

Primary endpoint
1 October 2027

1 October 2027

Quick facts

Lead sponsor	University of Calgary
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	128
Start date	20 March 2024
Primary completion	1 October 2027
Estimated completion	1 October 2027
Sites	1 location across Canada

Drugs / interventions tested

Psilocybin — full drug profile →

Conditions studied

Alcohol Use Disorder — all drugs for Alcohol Use Disorder →
Alcoholism — all drugs for Alcoholism →

Sponsor

University of Calgary

Who can join

Adults 22 to 65, any sex, with Alcohol Use Disorder or Alcoholism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to determine if a single dose of psilocybin administered with motivational enhancement therapy (MET) can reduce heavy drinking in patients with an alcohol use disorder (AUD).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Licit use of illicit drugs for treating depression: the pill and the process.
Torrado Pacheco A, Moghaddam B. · · 2024 · cited 2× · PMID 40047885 · DOI 10.1172/jci180217
Pharmacological interventions for alcohol use disorder: novel insights from recent clinical trials.
McManus KR, Ray LA. · · 2026 · PMID 41611606 · DOI 10.1080/17512433.2026.2625341

Verify or expand the search:

Other trials of Psilocybin

Trials testing the same drug.

NCT06885996 — Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence · Phase 2 · not yet recruiting
NCT07499583 — Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder · Phase 1, PHASE2 · not yet recruiting
NCT07226232 — Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression · Phase 3 · not yet recruiting
NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
NCT07506395 — Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder · Phase 1 · not yet recruiting

Other recruiting trials for Alcohol Use Disorder

Currently open trials in the same condition.

NCT06860607 — Environment and Alcohol: A Pilot Study · Phase 1 · recruiting
NCT07325266 — Human Laboratory Study of Apremilast for Alcohol Use Disorder · Phase 2 · recruiting
NCT07046819 — Tirzepatide in MetALD · Phase 2 · recruiting
NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting

Other University of Calgary trials

Trials by the same sponsor.

NCT06885996 — Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence · Phase 2 · not yet recruiting
NCT05729503 — Effect of SPG Block for Patients With Anxiety at Electronic Dance Music Festivals · Phase 2 · not yet recruiting
NCT07463339 — Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Cont · Phase 2 · not yet recruiting
NCT07145645 — Topical Diclofenac vs.Oral Ibuprofen for MSK Pain in Children · Phase 3 · recruiting
NCT07280325 — Moxie Self-Management and Education Support Program · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05995769 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Calgary
Last refreshed: 7 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05995769.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing